[
  {
    "article_id": 121,
    "article_title": "Pediatric Cardiology",
    "section_id": "01416fb2a0d04770ac92806830141765",
    "section_title": "Clinical Assessment and Management",
    "variant": "clinical",
    "imperatives": 3,
    "content": "**Initial Evaluation**\n\nBegin with a focused history addressing the presenting complaint, family history of cardiac disease, and functional capacity. Perform systematic physical examination including vital signs with age-appropriate blood pressure measurement, cardiac auscultation for murmurs and abnormal sounds, and assessment for signs of heart failure such as hepatomegaly or peripheral edema.\n\n**Diagnostic Testing**\n\nElectrocardiography should be interpreted using age-specific normal standards for infants and children. Select imaging based on clinical suspicion: echocardiography for initial structural assessment, cardiac MRI or CT for detailed anatomical definition when needed, and chest radiography to evaluate cardiac silhouette and pulmonary vascularity.\n\n**Chest Pain Evaluation**\n\nRecognize that most pediatric chest pain referrals represent low-probability cardiac cases. Obtain detailed characterization of pain quality, duration, triggers, and associated symptoms. Perform thorough physical examination and obtain electrocardiography. Reassurance and explanation of benign findings often suffice; cardiac imaging is reserved for cases with clinical features suggesting organic disease.\n\n**Blood Pressure Management**\n\nMeasure blood pressure using appropriately sized cuff with the child seated and at rest. Compare readings to age, sex, and height-specific reference standards. Elevated readings warrant confirmation on repeat visits before initiating pharmacological intervention.\n\n**Murmur Assessment**\n\nCharacterize murmurs by timing (systolic, diastolic, continuous), location, radiation, quality, and intensity. Correlate findings with clinical context, including growth and development, exercise tolerance, and associated symptoms. Innocent murmurs typically have characteristic features that distinguish them from pathological lesions; echocardiography confirms the diagnosis when clinical uncertainty exists."
  },
  {
    "article_id": 122,
    "article_title": "Immunodeficiency",
    "section_id": "0575f9ca53894d25807ca63ec2153bcb",
    "section_title": "Clinical Evaluation and Management",
    "variant": "clinical",
    "imperatives": 6,
    "content": "**Initial Assessment**\n\nSuspect primary immunodeficiency in children presenting with:\n- Recurrent infections requiring intravenous antibiotics\n- Recurrent deep-seated infections\n- Chronic oral or cutaneous candidiasis\n- Chronic diarrhoea with atypical features\n- Complications from live vaccines\n- Autoimmune disease or malignancy\n\n**Diagnostic Workup**\n\n1. Obtain detailed infection history (frequency, severity, type, response to treatment)\n2. Measure serum immunoglobulin levels (IgG, IgA, IgM)\n3. Assess specific antibody responses\n4. Perform B and T cell enumeration and functional studies\n5. Consider molecular genetic testing based on clinical phenotype\n6. Refer to immunologist for diagnosis confirmation and degree of immunodeficiency assessment\n\n**Immunisation Strategy**\n\nVaccine approach depends on immunodeficiency category:\n\n- **Selective IgA deficiency**: Administer all live-virus and inactivated vaccines as per standard schedule\n- **Major antibody deficiencies or SCID on immunoglobulin therapy**: Avoid routine inactivated vaccines (except inactivated [[298|influenza]] vaccine); inactivated vaccines may be given as part of pre-therapy immunologic assessment\n- **Common variable immunodeficiency**: Administer annual inactivated influenza vaccine; begin meningococcal conjugate vaccine (MenACWY) at 2 months of age due to splenic dysfunction and inadequate meningococcal antibody coverage in immunoglobulin replacement\n\n**Ongoing Management**\n\nCoordinate care with immunologist for:\n- Immunoglobulin replacement therapy decisions\n- Monitoring for complications (malignancy, autoimmunity, progressive organ involvement)\n- Gastrointestinal surveillance in conditions with known GI manifestations\n- Genetic counselling for family members"
  },
  {
    "article_id": 125,
    "article_title": "Pertussis",
    "section_id": "4436fdd5fc1140a9a4a3797ed995aca7",
    "section_title": "Management",
    "variant": "clinical",
    "imperatives": 6,
    "content": "**Diagnosis and initial assessment**\n\n- Obtain nasopharyngeal secretions for PCR or culture to confirm diagnosis\n- Perform complete blood count; expect leukocytosis with absolute lymphocytosis (though this may be absent in infants)\n- Obtain chest radiograph; look for obliteration of cardiac borders or signs of [[150|pneumonia]] and atelectasis\n- In infants, note that the characteristic inspiratory whoop may be absent and classic laboratory findings may not be present\n\n**Clinical evaluation**\n\n- Assess for paroxysmal cough pattern and posttussive vomiting\n- Monitor for [[151|respiratory distress]], cyanosis, apnea, bradycardia, and poor feeding in infants\n- Evaluate for complications including [[150|pneumonia]], [[315|seizures]], and signs of secondary [[278|bacterial infection]]\n- Distinguish from [[226|sepsis]] in infants by identifying paroxysmal cough pattern on examination\n- Note that auscultation of the chest is usually normal despite severe cough\n\n**Infection control**\n\n- Pertussis is highly communicable during the catarrhal and early paroxysmal cough stages (approximately 4 weeks after onset)\n- Implement appropriate respiratory isolation precautions"
  },
  {
    "article_id": 126,
    "article_title": "Ventricular Septal Defect",
    "section_id": "b7ba637741464906b0ae2be4f15ca09b",
    "section_title": "Clinical Assessment and Management",
    "variant": "clinical",
    "imperatives": 1,
    "content": "**Initial Evaluation**\n\nAssess the infant for signs of heart failure: failure to thrive, tachypnea, diaphoresis during feeding, hepatomegaly, and poor feeding tolerance. These symptoms typically emerge at 3–6 months of age in infants with large defects.\n\nPerform cardiac auscultation to identify a pansystolic murmur (which masks the first heart sound) and palpate for a thrill. Small defects may produce no murmur.\n\n**Diagnostic Confirmation**\n\nOrder echocardiography as the primary diagnostic modality. Request apical four-chamber views for perimembranous defects and short-axis views for muscular defects. Ensure color flow Doppler interrogation is performed, particularly for small muscular defects in the apical region.\n\nObtain a chest radiograph to assess for cardiomegaly, left atrial enlargement, and increased pulmonary artery flow.\n\n**Management Strategy**\n\n**Small defects** (< 3 mm): Observe clinically. No intervention is required in most cases, as spontaneous closure occurs in the majority. Follow-up echocardiography can be performed to document closure.\n\n**Large defects** (6–10 mm) with normal pulmonary vascular resistance and symptoms of heart failure: Refer for surgical evaluation. Surgery should be performed before age 2 years to prevent the development of pulmonary vascular obstructive disease.\n\n**Timing of intervention** depends on the clinical situation. Infants with symptoms of failure to thrive, significant tachypnea, and poor feeding at 3–6 months of age require correction at that time."
  },
  {
    "article_id": 128,
    "article_title": "Ankle Sprain",
    "section_id": "751dd986b8714b819ed43c083c835323",
    "section_title": "Management",
    "variant": "clinical",
    "imperatives": 6,
    "content": "**Initial Assessment**\n\n1. Examine for point tenderness over the anterior talofibular ligament and calcaneofibular ligament\n2. Test passive inversion—marked pain indicates ligament injury\n3. Assess weight-bearing ability; most children can bear slight weight\n4. Obtain X-rays in skeletally immature athletes to exclude fracture\n\n**Acute Phase (First 48–72 Hours)**\n\n- **Protection and immobilization**: Apply an air splint, elastic wrap, or ankle stirrup brace to support the ankle in a functional position (right angle)\n- **Rest**: Allow ambulation or exercise only if it causes no pain or swelling during activity or within 24 hours. Use crutches and light weight-bearing if pain occurs\n- **Ice**: Apply directly to the ankle for 20 minutes every 2 hours for the first 48 hours\n- **Compression**: Elastic wrap or air splint provides compression\n- **Elevation**: Elevate the extremity to reduce swelling\n- **NSAIDs**: Include as part of treatment regimen\n\n**Rehabilitation**\n\n- Begin functional rehabilitation as soon as possible\n- Focus on edema control, range of motion, strengthening, and proprioceptive restoration\n- Progress weight-bearing as tolerated\n- Refer for formal physical therapy\n- Prescribe a lace-up ankle brace for ongoing support and prevention of recurrence"
  },
  {
    "article_id": 129,
    "article_title": "Dysfunctional Uterine Bleeding",
    "section_id": "8894e114f3d34b4fbe04ac947cc8f886",
    "section_title": "Etiology and Pathophysiology",
    "variant": "long",
    "imperatives": 1,
    "content": "The most common cause of AUB in adolescents is anovulation secondary to immaturity of the hypothalamic-pituitary-ovarian axis, particularly during the first 1–2 years after menarche. However, AUB is a diagnosis of exclusion, and other causes must be investigated.\n\nOther potential causes include:\n\n- Thyroid dysfunction and hyperprolactinemia\n- Hypothalamic dysfunction related to exercise, stress, or changes in body weight\n- Bleeding disorders (including inherited coagulation defects)\n- Vaginal lacerations, hymenal tears, or foreign bodies\n- Sexually transmitted infections causing intermenstrual bleeding\n- Use of hormonal contraceptives or intrauterine devices\n- Vaginal adenocarcinoma (in girls whose mothers received diethylstilbestrol)\n- Psychosocial factors such as trauma or stress"
  },
  {
    "article_id": 129,
    "article_title": "Dysfunctional Uterine Bleeding",
    "section_id": "ceabf317c34d4f68bc36d6a6fe0feabb",
    "section_title": "Management",
    "variant": "clinical",
    "imperatives": 4,
    "content": "**Initial Assessment**\n\n1. Obtain detailed menstrual history: age at menarche, cycle length, duration of flow, volume of bleeding, and pattern of bleeding\n2. Screen for bleeding risk: history of easy bruising, nosebleeds, family history of bleeding disorders, and heavy bleeding in relatives\n3. Perform complete physical examination including vital signs, assessment for pallor or signs of [[349|anemia]], thyroid palpation, and pelvic examination as appropriate\n4. Measure hemoglobin or hematocrit\n\n**Stratification and Management**\n\n| Clinical Scenario | Management |\n|---|---|\n| Mild bleeding, normal hemoglobin, no contraceptive need | Observation and reassurance |\n| Low hemoglobin level (with or without other signs of iron deficiency) | Iron supplementation |\n| Symptomatic anemia or actively bleeding | Hospitalization |\n\n**Pharmacologic Options**\n\n- **Nonsteroidal anti-inflammatory drugs**: Ibuprofen or naproxen to reduce menstrual flow\n- **Combined hormonal contraceptives**: Highly effective for reducing or eliminating abnormal bleeding when appropriate for the adolescent\n\n**Further Investigation**\n\nBased on clinical findings, consider:\n\n- Thyroid function tests if thyroid dysfunction suspected\n- Coagulation studies if personal or family history of bleeding disorder\n- Testing for sexually transmitted infections if intermenstrual bleeding or risk factors present\n- Pelvic ultrasound if structural pathology suspected"
  },
  {
    "article_id": 132,
    "article_title": "Type 1 Diabetes Mellitus",
    "section_id": "2d08c10839074e0181f53b06ca4a077e",
    "section_title": "Management",
    "variant": "clinical",
    "imperatives": 1,
    "content": "**Initial Assessment and Diagnosis**\n\nConfirm diagnosis using American Diabetes Association criteria:\n- Fasting plasma glucose ≥126 mg/dL (7.0 mmol/L), OR\n- 2-hour plasma glucose ≥200 mg/dL (11.1 mmol/L) during 75-g oral glucose tolerance test, OR\n- Random plasma glucose ≥200 mg/dL (11.1 mmol/L) with classic hyperglycemia symptoms, OR\n- HbA1C ≥6.5%\n\nMeasure fasting or stimulated C-peptide to assess remaining beta cell function. Screen for autoantibodies (islet cell antibodies, anti-GAD, IA-2, insulin autoantibodies) to confirm autoimmune etiology.\n\n**Ongoing Management**\n\nImplement intensive insulin regimen with the following components:\n\n1. **Insulin dosing and timing**: Children receiving fixed-dose insulin should eat at consistent times coinciding with the peak action of the insulin preparation used. Adjust insulin doses based on food intake, physical activity, and blood glucose concentrations.\n\n2. **Flexible regimens**: Children using insulin pumps or basal-bolus regimens with long-acting basal insulin preparations (glargine, detemir) have flexibility in meal timing due to absence of significant peaks in basal insulins.\n\n3. **Dietary management**: Provide a balanced diet with carbohydrate counting matched to insulin administration.\n\n4. **Exercise**: Encourage regular physical activity as part of the management plan.\n\n5. **Blood glucose monitoring**: Perform essential monitoring to maintain near-normal glycemia.\n\n6. **Target glycemic control**: Maintain HbA1c <48 mmol/mol (6.5%) to reduce long-term complications.\n\n**Patient and Family Education**\n\nTeach adjustment of all diabetes regimen components (insulin, diet, exercise, monitoring). Establish a united team approach with unambiguous guidelines. Communicate progress promptly and use peer group support to promote adherence and health outcomes."
  },
  {
    "article_id": 133,
    "article_title": "Acute Asthma Exacerbation",
    "section_id": "2009346a94ce40b1a0f1ad1c5ecdfcc1",
    "section_title": "Management at the Bedside",
    "variant": "clinical",
    "imperatives": 1,
    "content": "**Immediate Assessment**\n\nRapidly evaluate severity using clinical signs:\n- Accessory muscle use, limited ability to speak, upright posture preference\n- Paradoxical pulse >25 mm Hg\n- Heart rate >130 bpm, respiratory rate >25 breaths/min\n- Peak expiratory flow <50% predicted\n- Oxygen saturation <92%\n- Any sign of life-threatening exacerbation (silent chest, drowsiness, confusion)\n\n**If any severe or life-threatening signs present: transfer to ED immediately**\n\n---\n\n**First-Line Therapy**\n\n1. **Supplemental oxygen** — administer as first-line therapy to maintain adequate oxygenation; close monitoring for deterioration is essential\n\n2. **Short-acting beta-agonist (SABA)** — frequent bronchodilator treatments\n   - Home treatment: 2–4 puffs via metered dose inhaler, or 1–2 puffs SABA in combination treatment\n\n3. **Systemic corticosteroids** — course of oral or intravenous corticosteroid\n   - Consider IV corticosteroids if patient unable to tolerate oral route\n\n---\n\n**Additional Considerations**\n\n- **High-dose ipratropium bromide** — addition leads to decreased rate of hospitalization\n- **Intravenous magnesium** — consider in severe exacerbations\n- **Caution with SABA dosing**: increasing frequency and dosage increases pulmonary blood flow through obstructed, poorly oxygenated areas, worsening ventilation/perfusion mismatch and hypoxemia if airway obstruction not resolved\n\n---\n\n**Follow-Up After ED or Hospitalization**\n\n- Outpatient follow-up within 1–2 days in children\n- Outpatient follow-up within 1 week in adolescents\n- Ensure written [[107|asthma]] action plan in place before discharge"
  },
  {
    "article_id": 134,
    "article_title": "Birth Asphyxia",
    "section_id": "f55c4ae0d169470ea61f9925579c5ab9",
    "section_title": "Management at the Bedside",
    "variant": "clinical",
    "imperatives": 5,
    "content": "**Initial Assessment and Approach**\n\nWhen an infant does not breathe at birth, assume secondary apnea is present and begin resuscitation immediately. Do not attempt to distinguish primary from secondary apnea clinically.\n\n**Immediate Actions**\n\n1. **Assess the infant's condition** using the Apgar score at 1 minute and 5 minutes after delivery, and at 5-minute intervals if the infant remains unwell. Evaluate heart rate, respiratory effort, muscle tone, reflex irritability, and colour.\n\n2. **Provide tactile stimulation** (drying, slapping the feet) as an initial measure, recognising that this may restart breathing in primary apnea but will not be effective in secondary apnea.\n\n3. **Initiate ventilatory support** without delay if the infant remains apnoeic or has inadequate respiratory effort after brief tactile stimulation. Ventilatory support must be provided within minutes to prevent death.\n\n**Ongoing Management**\n\nContinue resuscitative efforts according to current American Heart Association and American Academy of Pediatrics guidelines. Monitor heart rate, blood pressure, and oxygenation status. Assess for signs of neonatal neurologic dysfunction (seizures, encephalopathy, abnormal tone) and multiple organ involvement (renal, pulmonary, hepatic, cardiac, gastrointestinal dysfunction).\n\nNote: The reference passages do not provide specific drug doses, ventilation parameters, or detailed resuscitation protocols. Refer to current AHA-AAP resuscitation guidelines for complete management algorithms."
  },
  {
    "article_id": 135,
    "article_title": "Child Sexual Abuse",
    "section_id": "c534b7d5c13c45d78fb2c804b6259429",
    "section_title": "Clinical Evaluation and Management",
    "variant": "clinical",
    "imperatives": 3,
    "content": "**Initial Assessment**\n\nPerform a complete history and physical examination. Maintain a high index of suspicion based on nonverbal clues, psychosomatic symptoms, and presenting complaints such as vaginal itching or discharge.\n\n**Physical Examination Technique**\n\nConduct a systematic examination including:\n- Inspection of genital, perianal, and anal areas using appropriate terminology\n- Assessment for anal and perianal abnormalities\n- Evaluation for evidence of sexually transmitted infections\n- Identification of foreign bodies\n- Documentation of nongenital injuries\n- Careful distinction between normal anatomical variants and signs of abuse\n- Assessment for internal injury when indicated\n\n**Interview Process**\n\n- Interview the child separately from parents, using age-appropriate techniques\n- Minimize repetition of questioning to reduce trauma\n- Use drawings as communication aids if helpful\n- Interview parents separately\n- Document all information carefully\n\n**Documentation and Reporting**\n\n- Maintain a legal chain of evidence throughout evaluation\n- Use precise, objective documentation with appropriate anatomical terminology\n- Make a mandatory report to Child Protective Services if reasonable suspicion of abuse exists\n- Report regardless of whether abuse can be definitively proven\n- This obligation applies in all 50 states"
  },
  {
    "article_id": 136,
    "article_title": "Congenital Adrenal Hyperplasia",
    "section_id": "dc748e7bac0f48fba239a978070b4567",
    "section_title": "Management",
    "variant": "clinical",
    "imperatives": 1,
    "content": "**Recognition and Initial Assessment**\n\nSuspect CAH in any infant presenting with:\n- Ambiguous genitalia in a 46,XX infant\n- Salt-wasting crisis in a male infant aged 5–14 days: vomiting, weight loss, lethargy, poor feeding, [[99|dehydration]], tachycardia, or hypothermia\n- Abnormal newborn screening result (elevated 17-hydroxyprogesterone)\n\n**Immediate Investigations**\n\nObtain urgent blood tests:\n- Electrolytes (look for [[170|hyponatremia]] and hyperkalemia)\n- Glucose\n- Venous or arterial blood gas (assess for [[387|metabolic acidosis]])\n- 17-hydroxyprogesterone, renin, cortisol, and aldosterone levels\n- Perform ECG to assess for peaked T waves or arrhythmias from hyperkalemia\n\n**Acute Management of Salt-Wasting Crisis**\n\n1. **Fluid resuscitation:** Administer intravenous normal saline to correct [[161|severe dehydration]] and [[170|hyponatremia]]\n2. **Glucocorticoid replacement:** Initiate immediately\n3. **Mineralocorticoid replacement:** Required in salt-wasting forms\n4. **Electrolyte monitoring:** Recheck electrolytes frequently during acute phase\n5. **Cardiac monitoring:** Watch for arrhythmias related to hyperkalemia\n\n**Ongoing Glucocorticoid Dosing**\n\n- Classic CAH (salt-wasting and simple virilizing forms): 10–15 mg/m²/day\n- Nonclassical CAH: 6–10 mg/m²/day\n\n**Specialist Referral**\n\nArrange urgent referral to a pediatric endocrinologist. Management should involve a multidisciplinary team including endocrinology, genetics, urology, and psychosocial support, particularly for discussion of sex assignment and long-term management in virilized females."
  },
  {
    "article_id": 137,
    "article_title": "Dysmenorrhea",
    "section_id": "2cd0e14adecf4be3b229a06fdb0affef",
    "section_title": "Management",
    "variant": "clinical",
    "imperatives": 6,
    "content": "**Initial Assessment**\n\n1. Take a complete menstrual history including timing of pain, duration and severity\n2. Perform HEEADSSS psychosocial screening and detailed sexual history\n3. Explore hidden agendas (school avoidance, abuse history, secret sexual activity)\n4. Perform abdominal and pelvic examination (per vaginum in sexually active adolescents)\n5. Identify red flags for secondary dysmenorrhea: pain at menarche, intercycle pain, dyspareunia, abnormal discharge, pelvic mass or tenderness\n\n**First-Line Treatment: NSAIDs**\n\nStart as soon as the patient anticipates menstruation will begin:\n- **Naproxen**: twice daily (age and weight-appropriate dose)\n- **Ibuprofen**: every 6–8 hours (age and weight-appropriate dose)\n\nContinue on schedule throughout menstruation. Reassess after 2–3 menstrual cycles.\n\n**Second-Line Treatment: Hormonal Suppression**\n\nFor patients not responding to NSAIDs:\n- **Oral contraceptive pills (OCPs)**: used as for contraception. Inform patient that 2–3 cycles may elapse before maximal effect\n- **Levonorgestrel-releasing intrauterine device (LNG-IUD)**: effective for both primary and secondary dysmenorrhea\n- **Subdermal implant**: effective for both primary and secondary dysmenorrhea\n\nFor non-sexually active teenagers on OCPs, reassess therapy at 6–12 month intervals.\n\n**Investigation for Secondary Causes**\n\nIf pain persists despite appropriate NSAIDs and hormonal management for 6 months, or if red flags are present:\n- Arrange pelvic ultrasound\n- Consider pelvic MRI\n- Screen specifically for endometriosis (most common secondary cause)\n- Evaluate for Müllerian anomalies, obstructive reproductive tract anomalies, myomas and ovarian cysts\n\n**Note**: Acetaminophen-containing products are not recommended as they are less effective than NSAIDs for dysmenorrhea."
  },
  {
    "article_id": 138,
    "article_title": "Feeding Difficulty",
    "section_id": "4106c4c85fa747459095f671d9a4aec8",
    "section_title": "Clinical Approach",
    "variant": "clinical",
    "imperatives": 4,
    "content": "**Initial Assessment**\n\n1. **History and observation**: Observe a complete feeding session. Document feeding duration, volumes consumed, fatigue, respiratory symptoms, and vomiting or gagging. Ask about feeding schedule consistency, mealtime environment, and caregiver concerns.\n\n2. **Physical examination**: Assess for neurologic signs, craniofacial abnormalities, oral anatomy (lip closure, tongue position, ankyloglossia), and signs of aspiration (recurrent respiratory infections, chronic lung disease). Examine growth chart for recent decline or weight below 5th centile.\n\n3. **Determine organic versus nonorganic etiology**: This distinction guides further workup. Organic causes (neurologic impairment, cardiac disease, pulmonary disease, anatomic abnormality) require specific investigation. Nonorganic causes (schedule inconsistency, environmental factors, caregiver practices) require behavioral and environmental intervention.\n\n**Diagnostic Considerations**\n\n- **Swallowing assessment**: If concerns exist regarding pharyngeal phase physiology or aspiration risk, instrumental assessment of swallowing should be considered.\n- **Specific conditions**: [[171|Hypothyroidism]] is diagnosed through blood sample (low T3 and T4, high TSH). Prader-Willi syndrome presents with hypotonia in an otherwise normal child.\n- **Referral for specialist evaluation**: Consider occupational therapy or speech-language pathology for assessment of oral-motor difficulties and aspiration risk, particularly in preterm infants or those with [[82|developmental delay]].\n\n**Management Principles**\n\n- **Address correctable organic causes first**: Treat underlying conditions (e.g., [[245|gastroesophageal reflux]], cardiac disease, [[171|hypothyroidism]]).\n- **Environmental optimization**: Establish consistent feeding schedule. Position child in high chair when available. Remove distractions (television). Avoid ineffective positioning such as hammerlock hold in parent's lap.\n- **Feeding therapy**: Ongoing therapy for oral-motor difficulties may be required. Feeding evaluation and therapy may benefit infants with difficulty transitioning to solid foods or aspiration risk.\n- **Caregiver education**: Address nutritional knowledge, appropriate feeding techniques, and cultural food practices.\n- **Nutritional support**: If oral intake remains insufficient despite intervention, tube feeding should be considered."
  },
  {
    "article_id": 139,
    "article_title": "Head Trauma",
    "section_id": "eeabd6b38cbe4f02bcdd901b33ed850b",
    "section_title": "Bedside Management",
    "variant": "clinical",
    "imperatives": 5,
    "content": "**Primary Survey**\n\n1. **Airway and Breathing**: Secure the airway. Provide respiratory support if Glasgow Coma Scale is less than 8 or the child is responsive only to pain.\n\n2. **Circulation**: Assess vital signs. Obtain blood for full blood count and group and cross-match. Administer crystalloid 20 ml/kg and reassess. Note that shock does not occur from isolated head injury beyond infancy.\n\n3. **Disability**: Assess consciousness level. Examine pupil size and reactivity. If unequal pupils or concerns regarding head injury are present, initiate neuroprotection measures, arrange CT head imaging, and obtain neurosurgical consultation.\n\n4. **Exposure and Temperature Control**: Remove all clothing. Examine all parts of the body. Avoid hypothermia. Consider analgesia. Place a gastric tube (not nasal tube in head injury).\n\n**Secondary Survey**\n\nOnce the child's condition is stabilized, perform a complete secondary survey to identify all injuries. Consider X-rays of chest and pelvis. Seek surgical opinion if ruptured liver/spleen, fractured pelvis, or long bone fracture is suspected.\n\n**Special Populations**\n\nIn children with [[209|hemophilia]] and major head trauma, initiate immediate treatment with replacement therapy to achieve 100% factor activity level. For minor trauma without symptoms or external evidence of injury in mild hemophilia, replacement therapy may not be required; the physician must assess the type of trauma and bleeding history to determine need."
  },
  {
    "article_id": 140,
    "article_title": "Neonatal Fever",
    "section_id": "fb754fde9a8e4b4987a005b5e1cf1dd5",
    "section_title": "In short",
    "variant": "short",
    "imperatives": 1,
    "content": "- Fever is defined as ≥38°C but only ~50% of infected neonates develop fever; hypothermia may be the only sign\n- Neonatal immune defences are immature: decreased neutrophil function, low immunoglobulin G and complement, underdeveloped lymph node germinal centres\n- Common pathogens include Group B streptococcus, *E. coli*, *Listeria monocytogenes*, *Enterococcus*, *Staphylococcus aureus*, and HSV\n- Presentation is often nonspecific: irritability, lethargy, poor feeding, rash, jaundice, respiratory symptoms, hepatomegaly, or abdominal distention\n- Symptoms may begin on day 1 of life; severe disease typically emerges within the first 2 weeks\n- Physical examination alone cannot reliably predict serious infection\n- All febrile neonates require complete blood count, blood culture, urine culture, and CSF study; chest X-ray if respiratory cause suspected\n- All febrile neonates must be hospitalised and given intravenous antibiotics regardless of clinical appearance or initial lab results\n- Avoid ceftriaxone due to bilirubin displacement risk\n- Non-infectious causes (over-bundling, [[99|dehydration]] fever) may present with fever in a well-appearing infant"
  },
  {
    "article_id": 140,
    "article_title": "Neonatal Fever",
    "section_id": "70f71ff6ae3a4c72a65e05070662b1ad",
    "section_title": "Management of febrile neonates (0–28 days)",
    "variant": "clinical",
    "imperatives": 8,
    "content": "**Initial assessment:**\n- Obtain detailed history including maternal illness, delivery circumstances, and symptom onset\n- Perform thorough physical examination, repeated if necessary\n- Assess for danger signs: abnormal temperature (hypothermia <36°C or fever ≥38°C), tachypnea >60 breaths/min, [[151|respiratory distress]], apnea, tachycardia >180 beats/min, delayed capillary refill >3 seconds, weak or bounding pulses, abnormal abdominal or neurologic findings\n\n**Investigations (all febrile neonates):**\n- Complete blood count\n- Blood culture\n- Urine culture (via catheterisation or suprapubic aspiration)\n- Cerebrospinal fluid study and culture (lumbar puncture)\n- Chest X-ray if respiratory cause suspected\n\n**Empiric antibiotic therapy:**\nStart intravenous antibiotics immediately after investigations are sent, without awaiting results.\n\n*Neonates 0–7 days of age:*\n- Ampicillin PLUS Gentamicin\n- Some experts add a third or fourth generation cephalosporin if cerebrospinal fluid Gram stain shows gram-negative organisms\n\n*Neonates 8–28 days of age:*\n- Ampicillin PLUS Cefotaxime (or Ceftazidime or Cefepime if Cefotaxime unavailable)\n- Some experts add an aminoglycoside if cerebrospinal fluid Gram stain shows gram-negative organisms\n\n**Important considerations:**\n- Avoid ceftriaxone (risk of bilirubin displacement and hyperbilirubinaemia)\n- Admit all febrile neonates regardless of clinical appearance or initial laboratory results\n- Treat toxic-appearing neonates aggressively\n- For well-appearing febrile neonates with suspected non-infectious cause (over-bundling), maintain observation for [[226|sepsis]] signs\n- Specific antibiotic choice and duration should be guided by culture results and organism susceptibility once available\n- Some experts recommend repeat lumbar puncture to document cerebrospinal fluid sterility\n- Consider empiric acyclovir with surface, blood, and cerebrospinal fluid HSV sampling for infants at increased risk\n\n**Follow-up:**\n- Counsel parents on danger signs requiring immediate return\n- Arrange outpatient follow-up for infants with no identified focus on initial evaluation"
  },
  {
    "article_id": 141,
    "article_title": "Pediatric Dermatology",
    "section_id": "ccc88964091f4f0d8a0a37cf5d761d04",
    "section_title": "Clinical Assessment",
    "variant": "clinical",
    "imperatives": 2,
    "content": "**History and Examination**\n\nBegin with a systematic history addressing the onset, distribution, and progression of the rash. Document associated symptoms, triggers, and any treatments already attempted. Examine the lesions carefully, noting their morphology, distribution pattern, and any secondary changes.\n\n**Lesion Morphology**\n\nClassify lesions by type (papules, vesicles, pustules, plaques, erythema) as this guides the differential diagnosis. Papulosquamous and vesiculopustular eruptions are the most common presentations in children.\n\n**Special Considerations**\n\nFor pigmented lesions, particularly those involving the nail unit, document size, color uniformity, and any changes over time. Refer for specialist evaluation if there is diagnostic uncertainty or concerning features.\n\nFor neonatal presentations, consider the age of onset and associated systemic symptoms. Diaper dermatitis, seborrheic dermatitis, and vascular lesions require different management approaches.\n\n**Documentation**\n\nRecord findings with clear description of morphology and distribution. This documentation supports accurate diagnosis and guides appropriate management or referral."
  },
  {
    "article_id": 142,
    "article_title": "Altered Mental Status",
    "section_id": "5d9e2c5dcada45e89f1115282431ab21",
    "section_title": "Bedside Assessment and Management",
    "variant": "clinical",
    "imperatives": 5,
    "content": "**Initial Assessment**\n\nBegin with rapid evaluation of consciousness level and vital signs. Assess arousal by observing spontaneous activity and response to stimulation. Evaluate awareness by testing orientation to person, place, and time where age-appropriate.\n\n**Focused Neurologic Examination**\n\nExamine pupils for size, symmetry, and reactivity. Test extraocular movements for impairment. Assess motor function for focal weakness or asymmetry. Check reflexes for asymmetry. Look for meningeal signs (nuchal rigidity, Kernig sign). Observe for abnormal posturing, seizure activity, or involuntary movements.\n\n**Red Flag Findings Suggesting Structural Pathology**\n\n- Asymmetric or dilated pupils\n- Cranial nerve VI palsy\n- Focal weakness or asymmetrical reflexes\n- Abnormal posturing\n- Cushing triad (bradycardia, [[92|hypertension]], Cheyne-Stokes breathing)\n\n**Red Flag Findings Suggesting Infection**\n\n- Fever with headache, photophobia, and nuchal rigidity\n- Poor perfusion with fever ([[226|sepsis]])\n\n**Red Flag Findings Suggesting Trauma**\n\n- History of head injury\n- Scalp or skull hematoma or ecchymoses\n- Retinal hemorrhages (concerning for nonaccidental trauma)\n\n**Next Steps**\n\nBased on clinical presentation, obtain appropriate investigations: laboratory tests for metabolic causes (uremia, sepsis), lumbar puncture for CNS infection, neuroimaging (CT or MRI) for structural lesions, and EEG if seizure is suspected. Management is directed at the underlying cause once identified."
  },
  {
    "article_id": 143,
    "article_title": "Anaphylaxis",
    "section_id": "77853f6f9f0147cea2e1892186c9242a",
    "section_title": "Management",
    "variant": "clinical",
    "imperatives": 2,
    "content": "**Immediate Actions**\n\n1. Assess airway, breathing, and circulation\n2. Call for emergency help (911/EMS in community settings; resuscitation team in healthcare settings)\n3. Position the patient on their back or in a position of comfort if [[151|respiratory distress]] or vomiting is present\n4. Elevate the lower extremities\n5. Do not allow standing, walking, or running\n\n**Medication**\n\n**Epinephrine (adrenaline)** is the primary initial treatment:\n- Route: Intramuscular injection in the mid-outer aspect of the thigh\n- Administration: Use an epinephrine auto-injector (EA)\n- Second dose: May be given 5 to 15 minutes after the first injection if needed\n\n**Additional Supportive Care**\n\n- Supplemental oxygen\n- Intravenous fluids\n- Corticosteroids\n- H1 antihistamines\n- H2 antihistamines\n\n**Transport**\n\nTransport the patient to an emergency department, preferably by EMS vehicle, for further assessment and monitoring. Continued observation is essential because biphasic reactions can occur."
  },
  {
    "article_id": 144,
    "article_title": "Feeding Intolerance",
    "section_id": "18d9ae561259460889e834a9a8cfd36e",
    "section_title": "Management at the Bedside",
    "variant": "clinical",
    "imperatives": 3,
    "content": "**Step 1: Initial Recognition and Stabilization**\n\nIdentify feeding intolerance by presence of increased gastric residual volume, bilious or blood-stained stomach contents, abdominal distension, vomiting, diarrhea, bloating, or signs of microaspiration.\n\n**Step 2: Withhold and Observe**\n\nWithhold enteral nutrition for 6–12 hours. Observe closely for worrying symptoms (signs of necrotizing enterocolitis, sepsis, or acute deterioration).\n\n**Step 3: Decision Point Based on Clinical Course**\n\n*If no worrying symptoms and intolerance resolves:*\n- Restart enteral feeding\n- Proceed to Step 4\n\n*If worrying symptoms develop or clinical condition worsens:*\n- Withdraw enteral nutrition\n- Perform abdominal radiography and ultrasound\n- Repeat imaging every 6 hours\n- Observe for at least 48–72 hours\n- Once resolved, proceed to Step 5\n\n**Step 4: Minimal Enteral Feeding (if intolerance persists without worrying symptoms)**\n\n- Restart enteral feeding at 50% of the previous volume\n- Observe for at least 24 hours\n- If intolerance persists or reappears without worrying symptoms, proceed to Step 5\n- If no intolerance, advance feeding\n\n**Step 5: Feeding Regimen Modifications**\n\nAdjust one or more of the following:\n- **Schedule:** Change from bolus to continuous feeding\n- **Rate:** Decrease the infusion rate\n- **Concentration:** Concentrate the formula to decrease volume\n- **Formula:** Consider changing to a different formula\n- **Fluid intake:** Ensure adequate hydration\n\n**Step 6: Medical Management**\n\nConsider:\n- Acid-suppressing therapy for [[245|gastroesophageal reflux]]\n- Prokinetic agents to enhance gastric motility\n\n**Step 7: Advancement After Resolution**\n\nOnce feeding intolerance resolves, increase enteral nutrition by 20–30 ml/kg/day.\n\n**Ongoing Monitoring**\n\nA multidisciplinary team (physician and registered dietitian nutritionist) should:\n- Monitor enteral feeding tolerance at each assessment\n- Track growth trends\n- Review relevant laboratory values\n- If the child is also eating by mouth, evaluate the combination of tube and oral feedings to ensure adequate nutrient intake"
  },
  {
    "article_id": 145,
    "article_title": "Functional Abdominal Pain",
    "section_id": "eee00b22d506493f8803e627d930d022",
    "section_title": "Management at the Bedside",
    "variant": "clinical",
    "imperatives": 5,
    "content": "**Initial Assessment**\n\n1. Take a detailed history and perform a complete physical examination\n2. Identify red flag symptoms and signs: unintentional weight loss, blood in stools, persistent right upper or lower abdominal pain, persistent vomiting, dysphagia, odynophagia, arthritis, family history of [[254|inflammatory bowel disease]], or nocturnal diarrhea\n\n**If Red Flags Are Present**\n\nIf symptoms are consistent with [[193|acute abdomen]]:\n- Keep patient nothing by mouth\n- Request surgical consultation\n- Start antibiotics:\n  - **Piperacillin/tazobactam**: 350 mg/kg/day divided into doses every 6 hours (maximum 12 g/day), OR\n  - **IV meropenem**: 20 mg/kg every 8 hours (maximum 6 g/day), OR\n  - **Cefoxitin**: 30 mg/kg every 6 hours (maximum 12 g/day), OR\n  - **Cefotetan**: 30 mg/kg every 12 hours (maximum 12 g/day)\n- Arrange directed laboratory studies and imaging as indicated\n\n**If No Red Flags Are Present**\n\n1. Perform limited screening laboratory studies\n2. Reassure parents that no organic basis for pain exists\n3. Avoid prescribing placebo medications\n4. Counsel on behavioral and psychological approaches:\n   - Relaxation techniques (deep breathing exercises)\n   - Distraction strategies (conversation, television, games)\n   - Identification and management of psychosocial stressors\n5. Explain that symptoms typically improve on weekends and vacations\n6. Advise that most children improve with coping strategies alone\n7. Consider referral and consultation as indicated by clinical context"
  },
  {
    "article_id": 146,
    "article_title": "Hypertrophic Cardiomyopathy",
    "section_id": "7d2a3015193845d2bd2d4abd39b385dd",
    "section_title": "Management",
    "variant": "clinical",
    "imperatives": 10,
    "content": "**Initial Assessment**\n- Obtain ECG and echocardiography to confirm diagnosis and assess for LVOT obstruction\n- Perform exercise stress testing as part of risk stratification\n- Evaluate for [[334|syncope]] (especially exertional) as a major risk factor for sudden cardiac death\n- Obtain family history and refer for genetic counseling\n\n**Pharmacological Management**\n- Initiate negative inotropic agents:\n  - Beta-blockers (first-line)\n  - Calcium channel blockers (alternative)\n- Maintain adequate hydration; HCM is preload dependent and patients may benefit from higher rates of fluid administration\n- Avoid positive inotropes, medications that increase heart rate, and afterload-reducing agents\n\n**Activity and Lifestyle**\n- Implement moderate restriction of physical activity\n- Counsel against competitive athletics\n- Provide genetic counseling and recommend family member evaluation\n\n**Risk Stratification and Intervention**\n- Identify patients at increased risk for sudden cardiac death\n- Consider implantable cardioverter-defibrillator placement in high-risk patients\n- Refer symptomatic patients with subaortic obstruction for possible myectomy\n\n**Follow-up**\n- Arrange ongoing [[121|pediatric cardiology]] follow-up\n- Reassess risk stratification periodically"
  },
  {
    "article_id": 147,
    "article_title": "Meningitis",
    "section_id": "6acd91b043c140a3bcb4ad8fcab2e4db",
    "section_title": "Management",
    "variant": "clinical",
    "imperatives": 3,
    "content": "**Immediate Actions**\n\n- Any febrile child with a purpuric rash should receive intramuscular benzylpenicillin immediately and be transferred urgently to hospital without waiting for confirmatory tests\n- Obtain imaging (CT or MRI) before lumbar puncture to exclude hydrocephalus or mass lesion\n- Perform lumbar puncture and send cerebrospinal fluid for Gram stain, culture, and analysis\n- In patients with ventriculoperitoneal shunts, obtain cerebrospinal fluid via shunt tap if present\n\n**Antibiotic Therapy**\n\nFor shunt-related meningitis in patients who are seriously ill, initiate vancomycin and a third-generation cephalosporin (cefotaxime or ceftriaxone) to cover Staph aureus, coagulase-negative staphylococci (including methicillin-resistant strains), and gram-negative rods. In less seriously ill patients without shunt infection, therapy may be postponed while awaiting Gram stain and culture results.\n\n**Antibiotic Susceptibility Considerations**\n\nFor *Streptococcus pneumoniae* meningitis, interpret penicillin and cephalosporin susceptibility using meningitis-specific breakpoints:\n- Penicillin (intravenous): susceptible ≤0.06 mcg/mL; resistant ≥0.12 mcg/mL (no intermediate category)\n- Cefotaxime or ceftriaxone (intravenous): susceptible ≤0.5 mcg/mL; intermediate 1 mcg/mL; resistant ≥2 mcg/mL\n\n**Supportive Care**\n\n- Provide general and supportive measures as indicated\n- Monitor for syndrome of inappropriate antidiuretic hormone, which may accompany meningitis\n- Manage increased intracranial pressure from cerebral edema or hydrocephalus"
  },
  {
    "article_id": 148,
    "article_title": "Menorrhagia",
    "section_id": "8e247709f6b34a1cb7571821ff9b75f0",
    "section_title": "Management",
    "variant": "clinical",
    "imperatives": 8,
    "content": "**Initial Assessment**\n\n1. Obtain detailed menstrual history, including age at menarche, cycle regularity, and duration of amenorrhea\n2. Assess pubertal development (breast and pubic hair staging)\n3. Take confidential sexual history and screen for pregnancy\n4. Inquire about medications, hormonal contraceptive use, exercise intensity, dietary habits, stress, and systemic illness\n\n**First-Line Investigations**\n\nOrder the following tests:\n- Thyroid-stimulating hormone (TSH)\n- Prolactin\n- Follicle-stimulating hormone (FSH)\n- Human chorionic gonadotropin (HCG)\n- Pelvic ultrasound (for [[394|primary amenorrhea]])\n\n**Interpretation and Next Steps**\n\n**If FSH is low or normal:**\n- Suggests hypothalamic or pituitary dysfunction\n- Evaluate for eating disorders, excessive exercise, stress, systemic illness, and constitutional delay\n- Consider screening for celiac disease and other autoimmune disorders\n\n**If FSH is elevated:**\n- Suggests ovarian insufficiency\n- Repeat FSH testing\n- Evaluate for celiac and other autoimmune disorders\n- Consider karyotype analysis\n- Order pelvic and adrenal imaging\n- Arrange specialist referral\n\n**Bone Health Assessment**\n\nAfter 6 months or more of amenorrhea, perform bone densitometry to assess for low bone density, particularly in patients with functional hypothalamic amenorrhea or relative energy deficiency in sport.\n\n**Management of Hormonal Contraceptive-Related Amenorrhea**\n\nAmenorrhea occurring during hormonal contraceptive use does not require immediate investigation. However, if amenorrhea persists for 12 months after the last injection of medroxyprogesterone or for 6 months after discontinuation of birth control pills, rings, or patches, proceed with standard evaluation as outlined above."
  },
  {
    "article_id": 149,
    "article_title": "Nutritional Deficiency",
    "section_id": "1439818490bf46878149478d33e1bc0c",
    "section_title": "Management of Niacin Deficiency",
    "variant": "clinical",
    "imperatives": 6,
    "content": "**Diagnosis and confirmation:**\n- Obtain 24-hour urine niacin measurement\n- Measure RBC NAD/NADP number\n- Take detailed dietary history and assess for risk factors\n\n**Treatment:**\n- Niacin: 50–100 mg per dose, orally, three times daily for several weeks\n- Ensure dietary sources are adequate: beef, liver, fish, pork, wheat flour, eggs\n- Address underlying causes (e.g., medication review for isoniazid, anticonvulsants, antidepressants, 5-fluorouracil, 6-mercaptopurine, chloramphenicol, sulfonamides)\n\n**Monitoring:**\n- Assess resolution of gastrointestinal symptoms (diarrhea, anorexia)\n- Monitor skin changes (dermatitis, sun-exposed areas)\n- Evaluate neurological improvement (dementia, glossitis, angular stomatitis)"
  },
  {
    "article_id": 151,
    "article_title": "Respiratory Distress",
    "section_id": "0b3177a27aa74b4f89991b6cf3b55348",
    "section_title": "Bedside Management",
    "variant": "clinical",
    "imperatives": 2,
    "content": "**Initial Assessment and Stabilisation**\n\n1. **Airway, Breathing, Circulation (ABC)** — This is the first priority\n   - Assess airway patency urgently\n   - Determine breathing adequacy\n   - Evaluate circulation\n\n2. **Positioning and Airway Clearance**\n   - Position the child appropriately\n   - Perform oronasal suctioning if needed to clear secretions\n\n3. **Oxygen Delivery**\n   - Provide supplementary oxygen as needed\n   - Use oxygen hood or nasal prongs\n   - Monitor oxygen saturation (SpO₂)\n\n4. **Intubation**\n   - Intubate if airway patency cannot be maintained\n   - Note: Children have significant anatomical variation with age—shorter trachea, smaller tracheal diameter, and technically difficult intubation; risk of right mainstem intubation, tube dislodgement, or oesophageal intubation\n\n**Supportive Measures**\n\n5. **Temperature Management**\n   - Maintain normal temperature\n   - Correct hypothermia or hyperthermia\n\n6. **Fluid and Metabolic Support**\n   - Administer intravenous fluid boluses\n   - Correct hypoglycaemia\n\n7. **Respiratory Support**\n   - Consider CPAP (continuous positive airway pressure)\n   - Nebulisation with bronchodilators as indicated\n   - Positive pressure ventilation for severe cases\n\n8. **Specific Therapy for RDS**\n   - Surfactant replacement therapy for confirmed RDS\n   - Positive pressure ventilation for severe cases\n\n9. **Drainage**\n   - Intercostal tube drainage if air or fluid is present\n\n**Concurrent Assessment**\n\n- Simultaneously determine severity and type of respiratory problem\n- Obtain laboratory studies (CBC, arterial blood gas, serum electrolytes, blood culture) as indicated\n- Perform chest radiography\n- Pursue detailed evaluation to determine underlying aetiology"
  },
  {
    "article_id": 152,
    "article_title": "Tuberculosis",
    "section_id": "44625598c99f458cafc30d6bd46bda5e",
    "section_title": "Management of Congenital Tuberculosis",
    "variant": "clinical",
    "imperatives": 3,
    "content": "**Immediate Evaluation**\n- Tuberculin skin test\n- Interferon-gamma release assay\n- Chest radiography\n- Lumbar puncture\n- Appropriate cultures\n- Placental histology for granulomata and acid-fast bacilli\n- Placental culture for *M. tuberculosis* complex\n\n**Treatment (initiate promptly regardless of TST/IGRA results)**\n- Rifampin, once daily\n- Isoniazid, once daily\n- Pyrazinamide, once daily\n- Either ethambutol (RIPE regimen) OR aminoglycoside (streptomycin, kanamycin, or amikacin) OR capreomycin, once daily\n\n**If Meningitis Confirmed**\n- Add corticosteroids\n\n**Maternal Evaluation**\n- Assess for pulmonary and extrapulmonary tuberculosis, including genitourinary disease\n- Perform HIV testing (essential)\n- Perform drug susceptibility testing on maternal isolate"
  },
  {
    "article_id": 152,
    "article_title": "Tuberculosis",
    "section_id": "8908f4ca902847d2a4ef09f9844eb776",
    "section_title": "Management of Tuberculosis Meningitis",
    "variant": "clinical",
    "imperatives": 4,
    "content": "**Initial Assessment**\n- Perform lumbar puncture in all children <12 months with suspected TB disease; in children ≥12 months only if neurological signs or symptoms present\n- Obtain chest radiography and TST/IGRA\n- Send cerebrospinal fluid for culture and acid-fast bacilli examination\n\n**Drug-Susceptible *M. tuberculosis* Meningitis**\n\n*Intensive phase (2 months):*\n- Isoniazid, once daily\n- Rifampin, once daily\n- Pyrazinamide, once daily\n- Aminoglycoside OR ethionamide, once daily\n\n*Continuation phase (7–10 months):*\n- Isoniazid, once daily or twice weekly\n- Rifampin, once daily or twice weekly\n\n**Total duration:** 9–12 months\n\n**Drug-Susceptible *M. bovis* Meningitis**\n- At least 12 months of therapy without pyrazinamide\n\n**Geographic Considerations**\n- In areas with common streptomycin resistance, substitute kanamycin, amikacin, or capreomycin for aminoglycoside\n\n**Adjunctive Therapy**\n- Add corticosteroids if [[147|meningitis]] is confirmed\n\n**Drug Susceptibility Testing**\n- Perform on organism recovered from patient or mother"
  },
  {
    "article_id": 155,
    "article_title": "Congenital Infection",
    "section_id": "1afa5f09beb7457e94348d278d843c42",
    "section_title": "Clinical Evaluation and Management",
    "variant": "clinical",
    "imperatives": 6,
    "content": "**Initial Assessment**\n\nWhen congenital infection is suspected, obtain a detailed maternal history including primary infection timing, serologic status, and exposure risks. Perform thorough physical examination documenting growth parameters, hepatosplenomegaly, rash characteristics, jaundice, and neurologic findings.\n\n**Diagnostic Workup**\n\nFor suspected [[341|toxoplasmosis]]:\n- Obtain newborn and maternal serology: toxoplasma-specific IgG, IgM, IgA, and IgE\n- Send infant blood, cerebrospinal fluid, and amniotic fluid to reference laboratory for PCR detection of *Toxoplasma gondii*\n- Perform lumbar puncture\n- Arrange thorough ophthalmologic, auditory, and neurologic evaluation\n\nFor suspected CMV:\n- Test cord blood or infant urine for CMV by PCR or culture\n- Obtain CMV-specific serology if indicated\n\nFor suspected HHV-6:\n- Detect HHV-6A or HHV-6B DNA in cord blood by PCR\n\n**Interpretation of Serologic Results**\n\nCongenital infection is confirmed serologically by:\n- Persistent or increasing IgG antibody levels in infant compared to mother\n- Persistently positive IgG antibodies beyond the first year of life\n- Positive *Toxoplasma*-specific IgM or IgA antibody in infant\n- Persistence of other antibody types also indicates infant infection\n\n**Imaging and Additional Studies**\n\nFor symptomatic congenital CMV, obtain neuroimaging to assess for periventricular calcifications, cerebral atrophy, and hydrocephalus. Perform ophthalmologic examination to detect chorioretinitis. Arrange auditory assessment including formal audiometry."
  },
  {
    "article_id": 156,
    "article_title": "Infantile Hemangioma",
    "section_id": "e9df2fb7b0b34c4685b629d0d52f23d8",
    "section_title": "Management at the Bedside",
    "variant": "clinical",
    "imperatives": 3,
    "content": "**Initial Assessment**\n\nIdentify the hemangioma by location (superficial vs. deep), size, and appearance. Superficial lesions are bright red; deep lesions appear bluish. Document the age of onset and growth pattern. Assess for any functional impairment or complications.\n\n**Parental Counselling**\n\nEducate parents about the expected natural history: rapid growth over the first 3–4 months, plateau by 9–12 months, then gradual involution beginning after 12 months and typically completing by 4 years of age. Explain the potential for complications or permanent disfigurement and the rationale for watchful waiting versus intervention.\n\n**Treatment Options**\n\n**Topical therapy:** Topical timolol maleate may be prescribed for thin and/or superficial infantile hemangiomas.\n\n**Surgical and laser therapy:** Consider for selected hemangiomas causing functional impairment or significant disfigurement. Avoid surgery during the proliferating phase due to high vascularity and risk of blood loss. The optimal timing for surgical resection is between 3 and 4 years of age, when the lesion has stabilized and before the child's long-term memory and self-esteem formation begins.\n\n**Follow-up**\n\nMonitor lesions clinically during the proliferating and involuting phases. Imaging is typically reserved for deeper subcutaneous lesions without typical skin findings or when diagnosis is unclear."
  },
  {
    "article_id": 157,
    "article_title": "Lymphoma",
    "section_id": "fcbb08a0521d4223a33dd7efcd30cd32",
    "section_title": "Management",
    "variant": "clinical",
    "imperatives": 1,
    "content": "**Assessment and Diagnosis**\n\nEvaluate for worrisome lymphadenopathy features: systemic symptoms (fever, night sweats, weight loss), fixed nontender nodes, and supraclavicular involvement. Consider lymphoma in patients older than 3 years presenting with intussusception or abdominal symptoms (crampy pain, vomiting, obstruction, bleeding, palpable mass).\n\n**Treatment by Disease Extent**\n\n*Localized disease with complete surgical resection:*\n- Multiagent chemotherapy over 6 weeks\n- COPAD regimen: two cycles of cyclophosphamide, vincristine, prednisone, and doxorubicin\n- Expected 4-year overall survival: 99%\n\n*Advanced disease:*\n- Multiagent chemoimmunotherapy regimen\n- Duration: 4 to 6 months\n- Examples: FAB/LMB 96 protocol therapy or COG ANHL01P1 (which includes rituximab)\n- Treatment phases typically include reduction, induction, intensification, and maintenance therapy\n- 4-year overall survival: 95%\n\n*Gastrointestinal lymphoma:*\n- Combination of surgical resection and chemotherapy\n\n**Risk Stratification**\n\nTreatment intensity and specific protocols are adjusted based on risk stratification, including consideration of bone marrow and central nervous system involvement at presentation."
  },
  {
    "article_id": 158,
    "article_title": "Measles",
    "section_id": "b2faefea3cd4473291ddce2f76c85f33",
    "section_title": "Management",
    "variant": "clinical",
    "imperatives": 4,
    "content": "**Diagnosis and Confirmation**\n\n- Obtain IgM assay for serologic confirmation\n- Consider PCR or virus isolation from urine, blood, or throat/nasopharyngeal secretions if IgM unavailable\n\n**Isolation Precautions**\n\n- Implement standard and airborne precautions for all hospitalised patients\n- Maintain isolation from 7 days after exposure through 4–6 days after rash onset\n- For immunocompromised patients: continue isolation throughout the entire illness as viral shedding is prolonged\n- Exposed hospitalised patients: isolate for 5–21 days following exposure\n\n**Supportive Care**\n\n- Manage fever and symptoms with supportive measures\n- Monitor for secondary bacterial infections ([[160|otitis media]], bronchopneumonia, croup, diarrhea), which occur commonly in young children and immunocompromised hosts\n- Assess for complications including encephalitis and haemorrhagic manifestations\n\n**Exposure Management**\n\n- Susceptible individuals should avoid contact with infected patients during the infectious period\n- Unvaccinated or inadequately vaccinated close contacts require post-exposure evaluation and vaccination consideration"
  },
  {
    "article_id": 159,
    "article_title": "Neonatal Seizures",
    "section_id": "f0793185ec164aeeb43a3fbb645f1bc0",
    "section_title": "Management",
    "variant": "clinical",
    "imperatives": 1,
    "content": "**Initial Assessment and Stabilization**\n\nWhen a neonate presents with suspected seizure activity, immediate evaluation is essential. Ensure adequate oxygenation and ventilation. Distinguish true seizures from neonatal mimics such as jitteriness or benign sleep myoclonus (which occurs only during sleep and resolves on awakening).\n\n**Identification and Treatment of Reversible Causes**\n\nBefore starting antiseizure medication, identify and treat electrolyte abnormalities and hypoglycemia urgently, as these are rapidly reversible causes:\n\n- **[[321|Hypoglycemia]]**: Treat all seizing infants with glucose. Thresholds vary by postnatal age: <25–40 mg/dL in first 4 hours, <35–45 mg/dL from 4–24 hours, <45 mg/dL from 24–48 hours, <60 mg/dL thereafter\n- **[[368|Hypocalcemia]]**: Defined as calcium <8 mg/dL in infants >1,500 g birthweight; <7 mg/dL in very low birthweight infants\n- **Hypomagnesemia**: Assess and correct as indicated\n\n**Pharmacological Management**\n\nFor infrequent or transient seizures:\n- **Diazepam**: 0.1–0.5 mg/kg IV\n- **Lorazepam**: 0.1 mg/kg IV\n\nIf seizures do not stop, occur more frequently, or become more severe, escalate therapy. Respiratory support (ventilator in ICU setting) must be available whenever IV benzodiazepines or phenobarbital are administered.\n\nFor ongoing or repeated seizures requiring sustained control, antiseizure medications are used, though their efficacy in suppressing seizures is considerably poorer in neonates than in older children.\n\nFor refractory seizures, general anesthesia with endotracheal intubation is required. Agents used in this setting include continuous infusion of midazolam, propofol, ketamine, or pentobarbital.\n\n**Diagnostic Workup**\n\nConcurrently with seizure management, pursue investigation of underlying cause based on clinical presentation and timing of seizure onset. This may include neuroimaging, cerebrospinal fluid analysis, metabolic screening, and infectious disease evaluation as clinically indicated."
  },
  {
    "article_id": 160,
    "article_title": "Otitis Media",
    "section_id": "764e5ce1df9642f78771a78507b4116c",
    "section_title": "Management",
    "variant": "clinical",
    "imperatives": 3,
    "content": "**Diagnosis at the bedside**\n\nConfirm the diagnosis using pneumatic otoscopy. Look for:\n- Moderate to severe bulging of the tympanic membrane, OR\n- New-onset otorrhea not due to acute [[316|otitis externa]]\n\nSupporting features include rapid symptom onset, fever, otalgia or ear tugging, and recent upper respiratory tract infection history.\n\n**First-line treatment**\n\nAmoxicillin (oral): **80–90 mg/kg/day** for at least 7 days\n\nAlternative: Ceftriaxone (single dose) in certain cases\n\n**Second-line agents** (if first-line unsuitable):\n- Coamoxiclav\n- Cefaclor\n- Cefuroxime\n- Newer-generation cephalosporins\n- Macrolides (for penicillin and/or cephalosporin allergy)\n\n**Follow-up**\n\n- Repeat otoscopic examination at 3–4 days\n- Repeat otoscopic examination at 3 weeks\n\n**Do not prescribe**\n\n- Oral or topical decongestants (not necessary)\n- Antihistamines (ineffective and may precipitate sinus infection)\n- Antibiotics for [[258|otitis media with effusion]]\n\n**Special note**\n\nTympanocentesis is not performed routinely; treatment is empirical. Clinical features cannot reliably predict causative organism in individual children."
  }
]